Endocrinol Metab.  2023 Aug;38(4):392-394. 10.3803/EnM.2023.401.

The Current Status of Hyperthyroidism in Korea

• Kwon H

• KMID: 2545271
• DOI: http://doi.org/10.3803/EnM.2023.401

Reference

1. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J. 2018; 7:167–86.

2. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 26:1343–421.

3. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87:489–99.

4. Peeters RP. Subclinical hypothyroidism. N Engl J Med. 2017; 376:2556–65.

5. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017; 390:1550–62.

6. Smith TJ, Hegedus L. Graves’ disease. N Engl J Med. 2016; 375:1552–65.

7. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016; 388:906–18.

8. Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, Galofre JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014; 99:923–31.

9. Kim WG, Kim WB, Woo G, Kim H, Cho Y, Kim TY, et al. Thyroid stimulating hormone reference range and prevalence of thyroid dysfunction in the Korean population: Korea National Health and Nutrition Examination Survey 2013 to 2015. Endocrinol Metab (Seoul). 2017; 32:106–14.

10. Seo GH, Kim SW, Chung JH. Incidence & prevalence of hyperthyroidism and preference for therapeutic modalities in Korea. J Korean Thyroid Assoc. 2013; 6:56–63.

11. Kwon H, Jung JH, Han KD, Park YG, Cho JH, Lee DY, et al. Prevalence and annual incidence of thyroid disease in Korea from 2006 to 2015: a nationwide population-based cohort study. Endocrinol Metab (Seoul). 2018; 33:260–7.

12. Ahn HY, Cho SW, Lee MY, Park YJ, Koo BS, Chang HS, et al. Prevalence, treatment status, and comorbidities of hyperthyroidism in Korea from 2003 to 2018: a nationwide population study. Endocrinol Metab (Seoul). 2023; 38:392–4.

13. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009; 360:1574–5.

14. Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, et al. The role of propylthiouracil in the management of Graves’ disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009; 19:673–4.

15. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011; 21:593–646.

16. Moon JH, Yi KH. The diagnosis and management of hyperthyroidism in Korea: consensus report of the Korean Thyroid Association. Endocrinol Metab (Seoul). 2013; 28:275–9.

17. Kim HK, Yoon JH, Jeon MJ, Kim TY, Shong YK, Lee MJ, et al. Characteristics of Korean patients with antithyroid druginduced agranulocytosis: a multicenter study in Korea. Endocrinol Metab (Seoul). 2015; 30:475–80.